Allworth Financial LP Increases Holdings in Illumina, Inc. (NASDAQ:ILMN)

Allworth Financial LP raised its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 720.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,132 shares of the life sciences company's stock after acquiring an additional 6,263 shares during the period. Allworth Financial LP's holdings in Illumina were worth $1,001,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Golden State Wealth Management LLC purchased a new stake in shares of Illumina during the 4th quarter worth approximately $32,000. Versant Capital Management Inc raised its holdings in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after buying an additional 146 shares during the period. TD Private Client Wealth LLC raised its holdings in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock valued at $50,000 after buying an additional 141 shares during the period. V Square Quantitative Management LLC raised its holdings in Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company's stock valued at $52,000 after buying an additional 132 shares during the period. Finally, Spire Wealth Management raised its holdings in Illumina by 26.0% during the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company's stock valued at $63,000 after buying an additional 97 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Performance

ILMN stock traded down $3.00 during trading on Friday, hitting $94.20. 4,225,715 shares of the company traded hands, compared to its average volume of 2,990,509. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a 1 year low of $93.50 and a 1 year high of $156.66. The stock's 50-day simple moving average is $127.98 and its 200 day simple moving average is $134.01. The company has a market cap of $14.92 billion, a PE ratio of -12.27, a P/E/G ratio of 1.60 and a beta of 1.10.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Citigroup lowered Illumina from a "buy" rating to a "neutral" rating and decreased their price target for the company from $190.00 to $165.00 in a report on Wednesday, December 11th. UBS Group increased their price target on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. upped their price objective on Illumina from $125.00 to $140.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Robert W. Baird upped their price objective on Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a research report on Wednesday, November 6th. Finally, Morgan Stanley cut their price objective on Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.